Stuart Schreiber

Stuart Schreiber, Ph.D. is the Morris Loeb Research Professor at Harvard University, a co-Founder of the Broad Institute, Howard Hughes Medical Institute Investigator, Emeritus, and a member of the National Academy of Sciences and National Academy of Medicine.

He currently leads Arena BioWorks.

His work integrates chemical biology and human biology to advance the science of therapeutics.

Key advances include the discovery that small molecules can function as “molecular glues” that promote protein–protein interactions, the co-discovery of mTOR and its role in nutrient-response signaling, the discovery of histone deacetylases and (with Michael Grunstein and David Allis) the demonstration that chromatin marks regulate gene expression, the development and application of diversity-oriented synthesis to microbial therapeutics, and the discovery of vulnerabilities of cancer cells linked to genetic, lineage and cell-state features, including ferroptotic vulnerabilities.

His notable awards include the Wolf Prize in Chemistry and the Arthur Cope Award.

His approach to discovering new therapeutics guided many biotechnology companies that he founded, including Vertex Pharmaceuticals and Ariad Pharmaceuticals.

He has founded or co-founded 14 biotechnology companies, which have developed 16 first-in-human approved drugs or advanced clinical candidates.

Schreiber was born on February 6, 1956, in Eatontown, NJ to Mary Geraldine (Gerrie) Schreiber (née Ardoin) and Lieutenant Colonel Thomas (Tom) Sewell Schreiber.

From the ages of one to four he lived in a small village in France—Villennes-sur-Seine, about 30 kilometers west of Paris—with his family, where Tom Schreiber was stationed as a battalion commander at Supreme Headquarters Allied Powers Europe.

Shortly after returning to New Jersey, they moved to Fairfax, VA, where Tom Schreiber worked as an applied mathematician and physicist at Signal Corp on Fort Monmouth.

At age 61, Schreiber discovered that Tom Schreiber was not his biological father.

Schreiber attended Luther Jackson Junior High School in Falls Church, VA and graduated from Oakton High School in Fairfax, VA in 1973 after completing a 3-year work study program that prepared him for work in the construction field with on-the-job training and only a limited number of hours per week in the classroom, which he generally did not attend.

He did not take a chemistry class in high school.

Schreiber obtained a Bachelor of Science degree in chemistry from the University of Virginia in 1977, after which he entered Harvard University as a graduate student in chemistry.

He joined the research group of Robert B. Woodward and after Woodward's death continued his studies under the supervision of Yoshito Kishi.

In 1980, he joined the faculty of Yale University as an assistant professor in chemistry, and in 1988 he moved to Harvard University as the Morris Loeb Professor.

Schreiber started his research work in organic synthesis, focusing on concepts such as the use of [2 + 2] photocycloadditions to establish stereochemistry in complex molecules, the fragmentation of hydroperoxides to produce macrolides, ancillary stereocontrol, group selectivity and two-directional synthesis.

Notable accomplishments include the total syntheses of complex natural products such as periplanone B, talaromycin B, asteltoxin, avenaciolide, gloeosporone, hikizimicin, mycoticin A, epoxydictymene and the immunosuppressant FK-506.

Following his work on the FK506-binding protein FKBP12 in 1988, Schreiber reported that the small molecules FK506 and cyclosporin inhibit the activity of the phosphatase calcineurin by forming the ternary complexes FKBP12-FK506-calcineurin and cyclophilin-ciclosporin-calcineurin.

This work, together with work by Gerald Crabtree at Stanford University concerning the NFAT proteins, led to the elucidation of the calcium-calcineurin-NFAT signaling pathway.

The Ras-Raf-MAPK pathway was not elucidated for another year.

In 1993, Schreiber and Crabtree developed bifunctional molecules or “chemical inducers of proximity” (CIPs), which provide small-molecule activation over numerous signaling molecules and pathways (e.g., the Fas, insulin, TGFβ and T-cell receptors ) through proximity effects.

Schreiber and Crabtree demonstrated that small molecules could activate a signaling pathway in an animal with temporal and spatial control.

Dimerizer kits have been distributed freely resulting in many peer-reviewed publications.

Its promise in gene therapy has been highlighted by the ability of a small molecule to activate a small-molecule regulated EPO receptor and to induce erythropoiesis (Ariad Pharmaceuticals, Inc.), and more recently in human clinical trials for treatment of graft-vs-host disease.

In 1994, Schreiber and co-workers investigated (independently with David Sabitini) the master regulator of nutrient sensing, mTOR.

They found that the small molecule rapamycin simultaneously binds FKBP12 and mTOR (originally named FKBP12-rapamycin binding protein, FRAP).

Using diversity-oriented synthesis and small-molecule screening, Schreiber illuminated the nutrient-response signaling network involving TOR proteins in yeast and mTOR in mammalian cells.

Small molecules such as uretupamine and rapamycin were shown to be particularly effective in revealing the ability of proteins such as mTOR, Tor1p, Tor2p, and Ure2p to receive multiple inputs and to process them appropriately towards multiple outputs (in analogy to multi-channel processors).

Several pharmaceutical companies are now targeting the nutrient-signaling network for the treatment of several forms of cancer, including solid tumors.

In 1995, Schreiber and co-workers found that the small molecule lactacystin binds and inhibits specific catalytic subunits of the proteasome, a protein complex responsible for the bulk of proteolysis in the cell, as well as proteolytic activation of certain protein substrates.

As a non-peptidic proteasome inhibitor lactacysin has proven useful in the study of proteasome function.

Lactacystin modifies the amino-terminal threonine of specific proteasome subunits.

This work helped to establish the proteasome as a mechanistically novel class of protease: an amino-terminal threonine protease.

The work led to the use of bortezomib to treat multiple myeloma.

In 1996, Schreiber and co-workers used the small molecules trapoxin and depudecin to investigate the histone deacetylases (HDACs).

Prior to Schreiber's work in this area, the HDAC proteins had not been isolated.

Coincident with the HDAC work, David Allis and colleagues reported work on the histone acetyltransferases (HATs).

These two contributions catalyzed much research in this area, eventually leading to the characterization of numerous histone-modifying enzymes, their resulting histone “marks”, and numerous proteins that bind to these marks.

By taking a global approach to understanding chromatin function, Schreiber proposed a “signaling network model” of chromatin and compared it to an alternative view, the “histone code hypothesis” presented by Strahl and Allis.